Search research articles
Contact Us
Filters
Showing results (41-50 of 77) with videos related to
Page
of 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2013
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
Jean-Pierre Delord, Josep Tabernero, Rocío García-Carbonero, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 8, 2022
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study
Alain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, et al.
Targeted Oncology
|
April 13, 2021
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
Thomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, et al.
Oncotarget
|
April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
Norbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
Targeted Oncology
|
November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Plos One
|
December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H O'Neil, John M Wallmark, David Lorente, et al.
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, et al.
Cancer
|
September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin
Raffit Hassan, Christine Alewine, Idrees Mian, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 77) with videos related to
Sort By:
Page
of 8
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2013
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
Jean-Pierre Delord, Josep Tabernero, Rocío García-Carbonero, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 8, 2022
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study
Alain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, et al.
Targeted Oncology
|
April 13, 2021
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
Thomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, et al.
Oncotarget
|
April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
Norbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
Targeted Oncology
|
November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Plos One
|
December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H O'Neil, John M Wallmark, David Lorente, et al.
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, et al.
Cancer
|
September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin
Raffit Hassan, Christine Alewine, Idrees Mian, et al.
Page
of 8